Navigation Links
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
Date:2/16/2011

SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the first patient received subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze(™ technology (rHuPH20, recombinant human hyaluronidase). This represents the second Roche cancer medicine, in addition to Herceptin® SC (trastuzumab), to enter a Phase 3 registration study as part of the Halozyme-Roche collaboration. Initiation of the clinical trial has triggered a milestone payment of $5 million to Halozyme. MabThera is approved to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) using different induction and maintenance treatments that are currently given intravenously (IV).

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"The start of this Phase 3 subcutaneous MabThera trial in patients with follicular NHL signifies another major achievement for the Halozyme-Roche partnership, and represents the second Roche target to begin a pivotal trial. I congratulate the team on this important accomplishment," said Gregory Frost, Ph.D., Halozyme's president and CEO. "MabThera is the standard of ca
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
2. Halozyme Receives $5.5 Million Payment From Baxter
3. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
4. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
5. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics to Host Research Day for Investors and Analysts
8. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
9. Halozyme Therapeutics to Present at Upcoming Investor Conferences
10. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
11. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Nematicide is a type of chemical ... parasitic roundworms, found in massive quantities virtually everywhere—in ... animals. Nematicides have tended to be broad-spectrum toxicants ... through the soil. A single gram of soil ... more than 10,000 species classified, they are one ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
(Date:9/30/2014)... Fast, semi-automatic creation of ... documents ChemAxon , a leader ... for life science research, launches ChemCurator, an application ... from documents. Markush structures are essential ... and understanding Markush structures is a difficult and ...
(Date:9/30/2014)... Sept. 30, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Trademark Office (USPTO) issued U.S. Patent No. 8,816,083 ... Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid ... Use Thereof." The patent, which extends ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... CLINTON, N.J. and JERUSALEM, July 6 Ikaria Holdings, ... Ikaria has entered into an agreement to obtain a ... treatment for preventing pathological cardiac remodeling following acute myocardial ... phase I/II clinical trial, is administered via the coronary ...
... /PRNewswire-FirstCall/ - avVaa World Health Care Products Inc. (Pink ... of nationally branded therapeutic, natural skin and health care ... an agreement with 3PL Worldwide, Inc., for all Order ... CEO explains that "3PL Worldwide offers true multichannel support ...
... July 6 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: ... the $29.5 million of outstanding 8% Senior Convertible Notes due ... July 1, 2009 is effective as of 8:00 a.m. today. ... with holders of 87% of the Notes, which is above ...
Cached Biology Technology:IKARIA(R) to In-License BioLineRx's BL-1040 2IKARIA(R) to In-License BioLineRx's BL-1040 3avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaa's Product 2Verenium Completes Amendment to 8% Senior Convertible Notes 2Verenium Completes Amendment to 8% Senior Convertible Notes 3Verenium Completes Amendment to 8% Senior Convertible Notes 4
(Date:9/30/2014)... professor and Howard Hughes Medical Institute investigator, and ... recipients in the 2014 round of grants from ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... September 30, provides more than $3 million in ... , The BRAIN Initiative, launched last year, is ...
(Date:9/30/2014)... German . FRANKFURT. ... in the world. Because they grow underground, people use trained ... of truffles is not only of interest to gourmets. A ... the Goethe University Frankfurt have discovered that the smell of ... trapped inside truffle fruiting bodies. , White truffles from the ...
(Date:9/30/2014)... hope: A new research report published in October 2014 ... explains how scientists developed a synthetic version of a ... in human and mouse eggs similar to the natural ... fertilization. , "We believe that the results of this ... of human fertilization by providing a precise answer to ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... used topically in many skin creams and cosmetics because ... Now, new research just published in the Journal of ... and how it might actually benefit skin from the ... cocoa may actually help improve the appearance of women's ...
... is the only culprit in the steady increase in the ... challenged by a scientist speaking at the 22nd annual conference ... Prague, Czech Republic, Wednesday 21 June 2006. Professor ... that his research had shown that improved nutrition, both maternal ...
... (LANP) have unveiled the "nanoegg," the latest addition ... of the versatile nanoshell, nanoeggs are asymmetric specks ... harnessed for molecular imaging, medical diagnostics, chemical sensing ... July 18 issue of the Proceedings of the ...
Cached Biology News:New study reveals components of cocoa may enhance the appearance of the skin 2Nutrition a major factor in rise in twin pregnancies 2Nutrition a major factor in rise in twin pregnancies 3Rice scientists unveil 'nanoegg' 2